AR127110A1 - Composiciones farmacéuticas oftálmicas de roflumilast - Google Patents
Composiciones farmacéuticas oftálmicas de roflumilastInfo
- Publication number
- AR127110A1 AR127110A1 ARP220102541A ARP220102541A AR127110A1 AR 127110 A1 AR127110 A1 AR 127110A1 AR P220102541 A ARP220102541 A AR P220102541A AR P220102541 A ARP220102541 A AR P220102541A AR 127110 A1 AR127110 A1 AR 127110A1
- Authority
- AR
- Argentina
- Prior art keywords
- roflumilast
- ophthalmic pharmaceutical
- methods
- pharmaceutical formulations
- additionally
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical group FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002586 roflumilast Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 5
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940126534 drug product Drugs 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000005414 inactive ingredient Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a formulaciones farmacéuticas oftálmicas estables del inhibidor de fosfodiesterasa-4, roflumilast, y métodos para producirlas. Las novedosas formulaciones farmacéuticas oftálmicas de roflumilast pueden comprender un agente de viscosidad, un tensioactivo y un tampón. En las realizaciones preferidas, el pH de la composición farmacéutica oftálmica es de entre 6,0 y 6,7. Los métodos para preparar formulaciones farmacéuticas oftálmicas estables de roflumilast pueden incluir procesos separados de ingredientes activos e inactivos. Además, los métodos pueden incluir filtración por claridad para mitigar la agregación del tamaño de partículas y para crear una suspensión optimizada. Además, los métodos pueden incluir la esterilización terminal del medicamento final.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261404P | 2021-09-20 | 2021-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127110A1 true AR127110A1 (es) | 2023-12-20 |
Family
ID=85573381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102541A AR127110A1 (es) | 2021-09-20 | 2022-09-20 | Composiciones farmacéuticas oftálmicas de roflumilast |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230088371A1 (es) |
| EP (1) | EP4404970A1 (es) |
| JP (1) | JP2024533635A (es) |
| KR (1) | KR20240073906A (es) |
| CN (2) | CN116867480A (es) |
| AR (1) | AR127110A1 (es) |
| AU (1) | AU2022347454A1 (es) |
| CA (1) | CA3232173A1 (es) |
| IL (1) | IL311473A (es) |
| MX (1) | MX2024003419A (es) |
| WO (1) | WO2023044502A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311534A (en) * | 2021-09-22 | 2024-05-01 | Iolyx Therapeutics Inc | Methods for treating ocular inflammatory diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2354971T3 (es) * | 2002-05-28 | 2011-03-21 | Nycomed Gmbh | Uso oftalmológico de roflumilast para el tratamiento de enfermedades de los ojos. |
| DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| AU2006244245B2 (en) * | 2005-05-10 | 2010-11-18 | Alcon, Inc. | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
| KR20080029974A (ko) * | 2005-06-09 | 2008-04-03 | 산텐 세이야꾸 가부시키가이샤 | 로플루밀라스트 점안액 |
| AU2010325632B2 (en) * | 2009-12-03 | 2014-01-30 | Lupin Limited | Process for preparing pharmaceutical ophthalmic compositions |
| US9827191B2 (en) * | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2015132708A1 (en) * | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
| US9895359B1 (en) * | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| JP7499759B2 (ja) * | 2018-10-16 | 2024-06-14 | リサーチ トライアングル インスティテュート | 皮下生分解性リザーバデバイス |
-
2022
- 2022-02-10 CN CN202280014110.6A patent/CN116867480A/zh active Pending
- 2022-09-20 KR KR1020247013159A patent/KR20240073906A/ko unknown
- 2022-09-20 US US17/948,550 patent/US20230088371A1/en active Pending
- 2022-09-20 MX MX2024003419A patent/MX2024003419A/es unknown
- 2022-09-20 IL IL311473A patent/IL311473A/en unknown
- 2022-09-20 JP JP2024518131A patent/JP2024533635A/ja active Pending
- 2022-09-20 WO PCT/US2022/076726 patent/WO2023044502A1/en active Application Filing
- 2022-09-20 AR ARP220102541A patent/AR127110A1/es unknown
- 2022-09-20 AU AU2022347454A patent/AU2022347454A1/en active Pending
- 2022-09-20 CN CN202280072966.9A patent/CN118176023A/zh active Pending
- 2022-09-20 EP EP22871027.3A patent/EP4404970A1/en active Pending
- 2022-09-20 CA CA3232173A patent/CA3232173A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022347454A1 (en) | 2024-03-28 |
| MX2024003419A (es) | 2024-04-08 |
| JP2024533635A (ja) | 2024-09-12 |
| WO2023044502A1 (en) | 2023-03-23 |
| EP4404970A1 (en) | 2024-07-31 |
| KR20240073906A (ko) | 2024-05-27 |
| IL311473A (en) | 2024-05-01 |
| US20230088371A1 (en) | 2023-03-23 |
| CA3232173A1 (en) | 2023-03-23 |
| CN116867480A (zh) | 2023-10-10 |
| CN118176023A (zh) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
| PH12015502587A1 (en) | Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
| JP2019094356A (ja) | 眼科用水性組成物 | |
| AR127110A1 (es) | Composiciones farmacéuticas oftálmicas de roflumilast | |
| JP6868595B2 (ja) | 水性眼科組成物 | |
| AR059927A1 (es) | Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas | |
| JP2016188259A (ja) | 水性眼科組成物 | |
| JP2020073606A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
| JP2011132227A (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JP4751482B2 (ja) | コンタクトレンズ用液剤 | |
| JP2013181020A (ja) | 眼科用組成物 | |
| JP2011111441A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JP2011246383A (ja) | コンタクトレンズ装用者用疲れ目改善用眼科製剤 | |
| AR077458A1 (es) | Composiciones de copolimero en bloque de oxido de etileno oxido de butileno | |
| JP2006225323A (ja) | 水性外用組成物 | |
| JP2006248960A (ja) | 水性外用組成物 | |
| JP5650864B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JP2018203728A (ja) | 視覚機能の再活性化用眼科組成物 | |
| JP2012198538A (ja) | コンタクトレンズ用組成物 | |
| JP2017119693A (ja) | 眼科用組成物及びその製造方法 | |
| JP2021155414A (ja) | ソフトコンタクトレンズ用眼科組成物 | |
| JP2012198428A (ja) | コンタクトレンズ用組成物 | |
| RU2012130852A (ru) | Фармацевтическая композиция для местного применения при лечении воспалительных заболеваний глаз и способ ее использования | |
| JP2015028090A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| MX2022011131A (es) | Nuevo uso y metodo de tratamiento. |